ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 120 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2024. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $188,883 | +23.0% | 61,127 | +2.7% | 0.00% | – |
Q1 2024 | $153,608 | +8.4% | 59,538 | +5.1% | 0.00% | – |
Q4 2023 | $141,683 | +23.3% | 56,673 | +0.1% | 0.00% | – |
Q3 2023 | $114,929 | -6.7% | 56,615 | +5.7% | 0.00% | – |
Q2 2023 | $123,142 | -13.4% | 53,540 | +14.0% | 0.00% | – |
Q1 2023 | $142,273 | +34.6% | 46,955 | +3.5% | 0.00% | – |
Q4 2022 | $105,686 | +46.8% | 45,359 | +19.5% | 0.00% | – |
Q3 2022 | $72,000 | -24.2% | 37,965 | +8.3% | 0.00% | – |
Q2 2022 | $95,000 | +18.8% | 35,040 | +30.3% | 0.00% | – |
Q1 2022 | $80,000 | -19.2% | 26,898 | +6.0% | 0.00% | – |
Q4 2021 | $99,000 | -21.4% | 25,385 | -13.0% | 0.00% | – |
Q3 2021 | $126,000 | +65.8% | 29,180 | +15.9% | 0.00% | – |
Q2 2021 | $76,000 | -87.2% | 25,186 | -78.5% | 0.00% | – |
Q4 2017 | $592,000 | -15.4% | 117,321 | +3.9% | 0.00% | – |
Q3 2017 | $700,000 | +98.3% | 112,927 | +15.1% | 0.00% | – |
Q2 2017 | $353,000 | +10.0% | 98,090 | -0.7% | 0.00% | – |
Q1 2017 | $321,000 | – | 98,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
QVT Financial LP | 16,013,540 | $39,233,000 | 1.19% |
ARMISTICE CAPITAL, LLC | 1,940,000 | $4,753,000 | 1.12% |
DAFNA Capital Management LLC | 234,000 | $573,000 | 0.50% |
Alpha Wave Global, LP | 1,655,162 | $4,055,000 | 0.43% |
Telemetry Investments, L.L.C. | 150,000 | $368,000 | 0.21% |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 5,294,945 | $12,972,000 | 0.18% |
SABBY MANAGEMENT, LLC | 792,617 | $1,942,000 | 0.11% |
K2 PRINCIPAL FUND, L.P. | 443,887 | $1,088,000 | 0.10% |
Anson Funds Management LP | 105,085 | $257,000 | 0.08% |
DIALECTIC CAPITAL MANAGEMENT, LP | 25,000 | $61,000 | 0.03% |